Kevin Robert Lind - 30 Sep 2026 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Reporting relationship: Director
Issuer ticker: AVTX
Reported as of: 30 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Oct 2026, 16:15:31 UTC
Prior SEC filing: 30 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher Sullivan, Attorney-in-Fact

Key filing fact

Kevin Robert Lind filed Form 4 for Avalo Therapeutics, Inc. (AVTX) on 02 Oct 2026.

Key facts

This page summarizes Kevin Robert Lind's Form 4 filing for Avalo Therapeutics, Inc. (AVTX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Oct 2026, 16:15.

Change

Previous filing in this sequence was filed on 30 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001677036 Primary reporting owner

Lind Kevin Robert

Relationship: Director
Address: C/O AVALO THERAPEUTICS, INC., 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE
Signature: /s/ Christopher Sullivan, Attorney-in-Fact
Signature date: 02 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AVTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +1,352
Change %
Price: $12.29^*
Shares after: 1,352
Date: 30 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,352
Exercise price: $15.33
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The options were granted on September 30, 2026, and are 100% vested.

Footnote F2

The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees.